SCHEMBL2791869

SCHEMBL2791869

CCN(CC)c1ccc(C(=O)c2ccccc2C(=O)OC[C@@H](O)[C@H]2OC(=O)C(O)=C2O)c(O)c1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SMN1; SMN2 Q16637 4/20 0.53
▸ L3MBTL1 Q9Y468 3/20 0.53
▸ MEN1 O00255 2/20 0.53
▸ KMT2A Q03164 2/20 0.53
▸ MAPT P10636 5/20 0.45
▸ HSPD1 P10809 1/20 0.45
▸ HSPE1 P61604 1/20 0.45
▸ TST Q16762 1/20 0.45
▸ RECQL P46063 1/20 0.45
▸ BLM P54132 1/20 0.45
▸ TDP1 Q9NUW8 1/20 0.45
▸ ALDH1A1 P00352 4/20 0.43
▸ GAA P10253 2/20 0.43
▸ KDM4E B2RXH2 2/20 0.43
▸ POLB P06746 1/20 0.43
▸ LMNA P02545 4/20 0.36
▸ MAOB P27338 2/20 0.36
▸ TSHR P16473 1/20 0.34
▸ CA2 P00918 1/20 0.34
▸ CYP3A4 P08684 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2791873 1.00 SMN1; SMN2 (0.53) SMN1; SMN2L3MBTL1MEN1KMT2AMAPT
SCHEMBL13013522 0.91 MAPT (0.44) SMN1; SMN2L3MBTL1MEN1KMT2AMAPT
SCHEMBL3783878 0.90 ALDH1A1 (0.53) SMN1; SMN2L3MBTL1MEN1KMT2AMAPT
SCHEMBL3771212 0.90 ALDH1A1 (0.52) SMN1; SMN2L3MBTL1MEN1KMT2AMAPT
SCHEMBL3769984 0.90 ALDH1A1 (0.52) SMN1; SMN2L3MBTL1MEN1KMT2AMAPT
SCHEMBL3778699 0.90 ALDH1A1 (0.52) SMN1; SMN2L3MBTL1MEN1KMT2AMAPT
SCHEMBL3771807 0.90 ALDH1A1 (0.52) SMN1; SMN2L3MBTL1MEN1KMT2AMAPT
SCHEMBL3782310 0.87 ALDH1A1 (0.46) SMN1; SMN2L3MBTL1MEN1KMT2AMAPT
SCHEMBL13013520 0.87 ALDH1A1 (0.46) SMN1; SMN2L3MBTL1MEN1KMT2AMAPT
SCHEMBL13261881 0.85 L3MBTL1 (0.47) SMN1; SMN2L3MBTL1MEN1KMT2AMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9023889-B2 Use of ascorbic acid derivatives for the functionalization of matrices MERCK PATENT GMBH (DE) 2015-05-05 — — US disclosed
US-20100322881-A1 UVB FILTER BASED ON ASCORBIC ACID DERIVATIVES MERCK PATENT GESELLSCHAFT (DE) 2010-12-23 — — US disclosed
US-20100167936-A1 USE OF ASCORBIC ACID DERIVATIVES FOR THE FUNCTIONALIZATION OF MATRICES MERCK PATENT GESELLSCHAFT (DE) 2010-07-01 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100167936-A1 USE OF ASCORBIC ACID DERIVATIVES FOR THE FUNCTIONALIZATION OF MATRICES PROC, TTPA, COX6C SMN1; SMN2 1782/4885L3MBTL1 4596/4885MEN1 2468/4885
US-20100322881-A1 UVB FILTER BASED ON ASCORBIC ACID DERIVATIVES C1R, VDR, CYP2R1 SMN1; SMN2 4882/4885L3MBTL1 3989/4885MEN1 1235/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback